Has Walid Shaib, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,944,543 in general payments to Walid Shaib, MD across 629 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Walid Shaib, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Walid Shaib, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Walid Shaib, MD

Hematology & Oncology · New Haven, CTNPI 1831372481

Payments from drug & device makers

$1,944,543in general payments, 2019–2025

Across 629 payments — averaging $3091.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$539K
Novartis$490K
Lilly USA, LLC$370K
AstraZeneca$107K
Exelixis Inc.$98K
E.r. Squibb & Sons, L.L.C.$95K
plus $246K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	13	$539,207
Novartis	20	$489,782
Lilly USA, LLC	7	$369,925
AstraZeneca(2 entities)	57	$107,029
Exelixis Inc.	111	$97,530
E.r. Squibb & Sons, L.L.C.	28	$95,392
Merck	21	$61,125
Jazz Pharmaceuticals Inc.	30	$37,349
Seagen Inc.	43	$31,806
Lexicon Pharmaceuticals, Inc.	8	$29,842
Genentech, Inc.	9	$20,997
AbbVie	13	$20,473
Pfizer	36	$14,980
Incyte Corporation	7	$5,239
Tersera Therapeutics LLC	8	$3,982
Mylan Institutional Inc.	8	$3,437
Eisai Inc.	17	$2,944
ADC Therapeutics America, Inc.	1	$2,400
Janssen Scientific Affairs, LLC	2	$2,310
Taiho Oncology, Inc.	1	$1,400
Bayer	7	$1,035
Array Biopharma Inc	12	$855
Eli Lilly	2	$767
Johnson & Johnson	30	$724
Cumberland Pharmaceuticals, Inc.	2	$520
Bristol Myers Squibb	19	$411
Sobi, Inc	8	$375
Daiichi Sankyo Inc.	16	$338
Genentech USA, Inc.	13	$274
Gilead(2 entities)	12	$217
Rigel Pharmaceuticals, Inc.	4	$187
Boston Scientific	1	$166
Regeneron Healthcare Solutions, Inc.	6	$160
Karyopharm Therapeutics Inc.	6	$125
Advanced Accelerator Applications	1	$120
Ipsen Biopharmaceuticals, Inc	4	$120
Takeda Pharmaceuticals U.S.A., Inc.	4	$98
Astellas Pharma US Inc	4	$97
Amgen	5	$92
Beone Medicines USA, Inc.	4	$88
Caris MPI, Inc.	1	$53
Puma Biotechnology, Inc.	2	$46
Deciphera Pharmaceuticals Inc.	2	$43
Sanofi	1	$42
Mirati Therapeutics, Inc.	2	$40
Springworks Therapeutics, Inc.	2	$40
Agios Pharmaceuticals, Inc.	2	$39
Beigene USA, Inc.	2	$37
Syndax Pharmaceuticals, Inc.	2	$35
Foundation Medicine, Inc.	1	$28
AVEO Pharmaceuticals, Inc.	1	$26
Stemline Therapeutics Inc.	1	$26
CTI Biopharma Corp.	1	$22
Adaptive Biotechnologies Corporation	1	$21
Pharmaessentia USA Corporation	1	$19
EMD Serono, Inc.	1	$18
Boehringer Ingelheim	1	$17
Werfen USA LLC	1	$17
Acrotech Biopharma Inc.	1	$15
Helsinn Therapeutics (U.S.), Inc.	1	$15

How this compares

$1,944,543 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.

See all hematology & oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$119,995

Medicare patients

297

Services billed

1,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New Haven

Amer ZeidanNew Haven$15.5M
Nataliya UbohaNew Haven$13.3M
Michael CecchiniNew Haven$7.8M
Tarsheen SethiNew Haven$2.6M
Terri ParkerNew Haven$2.4M
Iris IsufiNew Haven$2.1M
Melinda YushakNew Haven$1.7M
Scott HuntingtonNew Haven$712K
Shalin KothariNew Haven$421K
Maximilian StahlNew Haven$240K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →